Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
  • 2020/02/13
サブ-ナビゲーション
  • information
  • News
  • Corporate Guide
    • Message from the president
    • Corporate Data
    • Value Creation Process
    • Corporate History
    • Corporate Executives
    • Group
    • Access
  • Business
    • Reagents/Instruments
    • CDMO
    • Gene Therapy
  • Investor Relations
    • Management Policy
      • Message from the President
      • Medium/Long-Term Management Plan
      • Governance
      • Business Risks
      • Action on Implement management that is conscious of cost of capital and stock price
    • Financial Data
      • Financial Highlights
      • Financial Indicators
      • Cash Flow
    • IR Library
      • Financial Results
      • Annual Securities Report
      • Annual Report
    • Stock Information
      • Stock Overview
      • General Meeting of Shareholders
      • Shareholder Return / Dividends
      • Stock Status
      • Stock Price
      • Articles of Incorporation, Share Handling Regulations
    • IR Calendar
    • 現在位置:IR News
    • FAQ
    • Contact IR
    • Disclosure Policy
    • User Guide
  • Sustainability
    • News＆Topics
    • Policy
    • Materiality （Important Issues）
      • Governance
      • Environment
      • Human rights
      • Wellness
      • Safety
      • Human resources
      • Procurement
      • Community
    • Sustainability Topics
    • Sustainability Index
  • Contact Us
    • Contact IR

Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]

  • 2020/02/13

Back to List

PAGETOP
PAGETOP
  • CLOSE
  • MENU

サイト内検索

  • footer-content
  • menu
  • JA
  • EN
  • contact
  • gnavi-box